Minneapolis Star Tribune — Chris Pulling, CEO of MicroOptx, is looking forward to human trials beginning late summer or early fall on the implant that the medical device company is developing that it says can cure glaucoma.
Pulling said nonclinical and animal tests show the company’s device, implanted through the eye’s surface, halts the progression of glaucoma, which can cause blindness.
The device, which houses nano-engineered flow channels to shunt fluid from inside the eye to reduce pressure that damages the optic nerve, is the thickness of about 1½ human hairs, Pulling said.
Read more: http://www.startribune.com/movers-shakers-microoptx-ceo-chris-pulling/371865581/
